Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsMEX:NVST 80 EBITDA Margin % is 13.88% as of Mar. 2026, which is 16% below its 10-year median of 16.45. GuruFocus rates MEX:NVST with a GF Score™ of 80/100 and a GF Value™ of MXN332.83. The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Envista Holdings ranks better than 62.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Envista Holdings's EBITDA for the
three
months ended in Mar. 2026 was MXN1,765 Mil. Envista Holdings's Revenue for the
three
months ended in Mar. 2026 was MXN12,722 Mil. Therefore, Envista Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 13.88%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Envista Holdings EBITDA Margin % Related Terms
Envista Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Envista Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVST vs MMSI, MMED, STVN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Envista Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Envista Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings (MEX:NVST) has a EBITDA Margin % of 13.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Envista Holdings and its competitors. This is 16% below median its historical median of 16.45. According to the industry distribution chart, Envista Holdings ranks #306 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 37.5%.
Is Envista Holdings' EBITDA Margin % too high?
Envista Holdings' current EBITDA Margin % of 13.88% is 16% below median its 10-year median of 16.45. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Envista Holdings' value of 13.88% is 85.8% above this industry median. Based on the distribution chart, Envista Holdings ranks #306 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Envista Holdings has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' EBITDA Margin % compare to MMSI and MMED?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #306 out of 815 companies for EBITDA Margin %. This puts Envista Holdings in the upper half of its industry. The industry median EBITDA Margin % is 7.47. Envista Holdings' value of 13.88% is 85.8% above this benchmark. While the company's 10-year median is 16.45 vs. the industry median of 7.47, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current EBITDA Margin % of 13.88% is 85.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current EBITDA Margin % is 13.88%, which is 16% below median its own 10-year median of 16.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Envista Holdings (MEX:NVST) has a current EBITDA Margin % of 13.88%. The stock's GF Value™ is MXN332.83, compared to a current price of MXN370.00 — trading 11.2% above its estimated fair value. The current EBITDA Margin % is 13.88%, which is 16% below median its 10-year median of 16.45 and 85.8% above the Medical Devices & Instruments industry median of 7.47. Envista Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Envista Holdings (MEX:NVST), the current EBITDA Margin % is 13.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (MEX:NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of MXN370.00 is trading 11.2% above its estimated GF Value™ of MXN332.83.
Key valuation signals for MEX:NVST:
EBITDA Margin %: 13.88% (16% below median its 10-year median of 16.45)
GF Value™: MXN332.83 vs. price of MXN370.00 (11.2% above fair value)
Industry Position: 85.8% above the Medical Devices & Instruments median (#306 of 815)
No single metric tells the full story. See the MEX:NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
80GF Score
Get the complete analysis for MEX:NVST
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVST has been successfully added to your 
